May 17, 2023 4:01 pm EDT MindMed Announces Enrollment Milestone in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)
May 04, 2023 4:02 pm EDT MindMed Reports First Quarter 2023 Financial Results and Business Highlights
May 02, 2023 8:00 am EDT MindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing Strategy
May 01, 2023 4:01 pm EDT MindMed to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update
Apr 14, 2023 7:00 am EDT MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial of Lysergide (LSD) in Major Depressive Disorder (MDD)
Apr 13, 2023 7:00 am EDT MindMed Appoints Mark R. Sullivan as Chief Legal Officer and Corporate Secretary